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ABSTRAK 
PEMANTAUAN TEKANAN DARAH DI RUMAH (‘HBPM’) DAN KESANNYA KE 
ATAS TEKANAN DARAH DI KLINIK DAN PEMATUHAN PENGAMBILAN 
UBATAN, DALAM KALANGAN PESAKIT HIPERTENSI DI KLINIK PRIMER 
HOSPITAL UNIVERSITI 
Pengenalan: 
‘HBPM’ kini semakin popular dan penggunaannya kini disyorkan oleh garis 
panduan tempatan dan antarabangsa dalam pengurusan kes hipertensi. 
Objektif: 
Untuk mengkaji kesan ‘HBPM’ terhadap tekanan darah klinik dan pematuhan 
pengambilan ubatan di kalangan pesakit hipertensi di Klinik Primer Hospital 
Universiti. 
Metodologi: 
Satu kajian rawak telah dijalankan dari Disember 2014 hingga April 2015, 
melibatkan 88 pesakit yang dibahagikan kepada kumpulan intervensi (yang 
melakukan ‘HBPM’) dan kumpulan kawalan. Pematuhan pengambilan ubatan 
diukur dengan menggunakan borang soal selidik Penilaian Komplian Ubat-
Ubatan yang telah disahkan. Pesakit dilihat pada lawatan permulaan dan 
selepas dua bulan intervensi. Tujuan utama adalah untuk menilai perbezaan 
bacaan tekanan darah klinik dan skor pematuhan pengambilan ubatan sebelum 
dan selepas intervensi, melibatkan perbandingan dalam kumpulan dan di 
antara kumpulan.     
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Keputusan: 
Bagi perbandingan dalam kumpulan; perubahan min tekanan darah sistolik 
(‘SBP’), tekanan darah diastolik (‘DBP’) dan skor pematuhan pengambilan 
ubatan (‘MAS’) adalah signifikan secara statistik. Namun, perubahan ini lebih 
ketara dilihat pada kumpulan intervensi berbanding kumpulan kawalan (‘SBP’ 
17.6mmHg, ‘DBP’ 9.5mmHg, ‘MAS’ 1.5 vs ‘SBP’ 14.3mmHg, ‘DBP’ 6.4mmHg, 
‘MAS’ 1.3). Selepas dua bulan, perbandingan di antara kumpulan menunjukkan 
perbezaan min terlaras bagi min ‘SBP’= 4.74 (95% CI -0.65 mmHg to 10.13 
mmHg) (p=0.084); min ‘DBP’ = 1.41(95% CI -2.01 mmHg to 4.82 mmHg) 
(p=0.415) dan min ‘MAS’= 0.05 (95% CI -0.29 mmHg to 0.40 mmHg) (p=0.768). 
Tiada perbezaan yang signifikan bagi kesemua pembolehubah bagi 
perbandingan antara kumpulan di akhir kajian. 
Kesimpulan: 
Intervensi ‘HBPM’ selama 2 bulan menunjukkan penurunan bacaan tekanan 
darah klinik dan penambahbaikan dalam pematuhan pengambilan ubatan 
walaupun ianya tiada perubahan yang signifikan berbanding penjagaan 
hipertensi biasa. Oleh itu, kajian lanjut dengan tempoh yang lebih lama 
disarankan untuk menentukan kesan jangka panjang ‘HBPM’ ini.     
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ABSTRACT 
HOME BLOOD PRESSURE MONITORING (HBPM) EFFECT ON OFFICE 
BLOOD PRESSURE AND MEDICATION ADHERENCE AMONG 
HYPERTENSIVE PATIENTS ATTENDING PRIMARY CARE CLINIC IN 
UNIVERSITY HOSPITAL 
Introduction: 
HBPM usage is increasingly popular nowadays and it is widely recommended 
by local and international guideline as part of the hypertensive care. 
Objectives: 
To evaluate HBPM effect on office BP and medication adherence among 
hypertensive patients attending primary care clinic in university hospital 
Methods: 
A randomized controlled trial was conducted from December 2014 to April 
2015, involving 88 patients, allocated to either HBPM group or control group. 
Medication adherence was measured by a validated new Medication Adherence 
Score (MAS) questionnaire. Patients were seen at baseline and two months 
after intervention. The primary outcomes were to evaluate the differences of 
office BP and MAS at baseline and at two months within groups and in between 
groups.   
 Results: 
For within group comparison, the mean changes of systolic BP (SBP), diastolic 
BP (DBP) and MAS were statistically significant for both groups. However, the 
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mean changes were greater seen in HBPM group than the control group (SBP 
17.6mmHg, DBP 9.5mmHg, MAS 1.5 vs SBP 14.3mmHg, DBP 6.4mmHg, MAS 
1.3). For comparison in-between group at two months, the adjusted mean 
difference for: mean SBP was 4.74 (95% CI -0.65 mmHg to 10.13 mmHg) 
(p=0.084); mean DBP was 1.41(95% CI -2.01 mmHg to 4.82 mmHg) (p=0.415) 
and mean MAS was 0.05 (95% CI -0.29 mmHg to 0.40 mmHg) (p=0.768). 
There were no significant differences between the two groups in all variables at 
2 months of the study 
Conclusion: 
HBPM of two months results in greater reduction of office BP and improvement 
in medication adherence even though it is statistically no difference to usual 
care. Therefore, further studies with longer duration are recommended to 
assess the long term effect of HBPM. 
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CHAPTER 1: INTRODUCTION AND LITERATURE REVIEW 
Hypertension (HPT) is an important public health problem and it contributes to 
4.5% of the disease burden worldwide (1). Globally, the prevalence of HPT in 
adults (≥25 years old) was around 40% with the number of uncontrolled HPT 
estimated around 1 billion in 2008 (2). World Health Organization (WHO) 
reported that 9.4 million deaths each year (13%) are attributed to HPT with 45% 
and 51% of deaths are due to heart disease and stroke respectively. This 
correlates with the fact that HPT is an established modifiable risks factor for 
cardiovascular,  cerebrovascular and kidney disease (3-5). The burden of 
hypertensive-related morbidity and mortality is increasing year by year and this 
substantially contributes to the escalating costs of health care (6). 
In Malaysia, as reported in the National Health and Morbidity Survey (NHMS) 
2015; it was estimated that the prevalence of HPT in individuals aged 18 years 
and above was 30.3% (4). It was reported that the proportion of “undiagnosed 
HPT” still remained high at 17.2% with the finding of every two “diagnosed 
HPT”, there are three “undiagnosed HPT” (a ratio of 2:3) (4). Among those 
diagnosed with HPT, only about one-third of them (34.8%) achieved BP target 
of control (5). With the magnitude of problems as stated above, much effort 
need to be done in order to reduce the hypertensive prevalence to lesser than 
24%; as to achieve the national target for year 2025 (4) and at the same time to 
tackle the issue of undiagnosed hypertension and failure to achieve BP control. 
The National Strategic Plan for Non-Communicable Diseases (NSP-NCD) is 
among steps taken by our government in order to address the above issue. 
Prevention and promotion, clinical management, increasing patient compliance, 
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action with NGOS, professional bodies and other stakeholders, monitoring, 
research and surveillance, capacity building; and policy and regulatory 
interventions are among the seven strategies outlined in the NSP-NCD (7). The 
clinical management and monitoring part of the patients can be improved with 
the usage of out-off office BP measurement, in particular home-blood pressure 
monitoring.   
Out-of-office blood pressure (BP) measurement defined as BP reading which is 
obtained from out of the clinic setting. This includes 24-hour ambulatory BP 
monitoring (ABPM) and home BP monitoring (HBPM). The usage of ABPM and 
HBPM are now gaining popularity in the management of hypertension (8), 
particularly in overcoming the limitation of office blood pressure measurement 
(OBPM).  
Although OBPM is still considered as a gold standard for BP reading, there are 
several disadvantages that limit its use. In view of random fluctuations of BP 
throughout the day (BP variability) and the white-coat effect, OBPM is not 
representative of a patient’s true BP (9). Consequently, there will be an 
overestimation of patient’s BP, leading to unnecessary drug prescription (10). 
Therefore, a proper diagnosis and careful patients selection in starting 
treatment is very important and the usage of ABPM / HBPM may accomplish 
this objective.  
1.1 AMBULATORY BP MONITORING (ABPM) 
ABPM is first illustrated more than 40 years ago and traditionally it can provide 
the following three types of information, which include an estimation of “true” BP 
reading, the diurnal rhythm of BP, and BP variability (11). It provides multiple 
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BP measurements at specific intervals within 24- to 48-hours period. Thus, by 
reflecting the patient’s actual BP, it shows a better estimate of end-organ 
damage associated with hypertension and gives a better prediction of 
cardiovascular events (12). It is also particularly useful in the clinical situation 
such as “white-coat” hypertension, drug-resistant hypertension, symptomatic 
hypotension or hypertension especially in the elderly (12) (13).  
Despite its proven benefits, ABPM is currently limited for clinical use in view of 
its current cost and not widely available (13). With the limited clinical usage of 
ABPM, home blood pressure measurement (HBPM) now can be an alternative 
to ABPM and may have similar prognostic value. In view of its lower cost and 
greater patient’s convenience; HBPM use is more popular than ABPM (13). 
1.2 SELF-MONITORING OR SELF-MEASUREMENT OF BP (SMBP) / HOME 
BLOOD PRESSURE MONITORING (HBPM) 
HBPM is introduced in the 1930s and its usage now is gaining acceptance 
among hypertensive patients (14). At present, in developed countries up to 70% 
of hypertensive patients are regularly assessing their BP at home (8). In 
Malaysia, Beth MRM found that 32.3% of hypertensive patient (whom 
hospitalized in a private hospital) are doing their home BP monitoring at home 
(15). 
HBPM has many proven benefits compared to OBPM. A systematic review by 
Stergiou GS has shown that HBPM is better in term of diagnosing uncontrolled 
hypertension, assessing treatment response and improving patients 
compliance, thus potentially provides cost saving (13). Therefore, HBPM usage 
is now generally acknowledged by physicians worldwide (8). 
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1.2.1 Advantages of HBPM:  
HBPM is proven to have several advantages over OBPM, and it is less costly 
and user-friendly compared to ABPM. With the recent technologies, the HBPM 
monitors (which use the oscillometric method for measurement) are now using 
an automated BP machine which are more reliable and show accurate readings 
(16). It allows multiple readings to be taken at person’s usual environment and 
at their normally active day. Therefore, it provides a “true” BP value that is 
devoid of the white coat and placebo effects (16).   
HBPM reading is shown to be lower than clinic BP (systolic BP of 10-20 mmHg, 
diastolic BP of 5-10 mmHg) (9, 13), and its readings are closer to the average 
BP recorded by ABPM; thus it serves the best predictor for cardiovascular risk 
(16). Therefore, it can improve a diagnostic and predictive accuracy.  
1.2.1.1 HBPM and its evaluation of white-coat hypertension and white-coat 
effect 
White-coat hypertension is defined as high BP reading that occurs only in a 
medical care setting. An individual is hypertensive during repeated OBPM 
(>140/90 mmHg), but ABPM/HBPM is normal (<135/85 mmHg); and it involves 
20% of patients with established diagnosis of hypertension. White-coat effect is 
the phenomenon that leads to it, whereby it is related to anxiety or a hyperactive 
alerting response. The specificity of HBPM to detect this problem is 88.6%, and 
the sensitivity is 68.4% (13, 16, 17).     
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1.2.1.2 HBPM and its evaluation of masked hypertension 
Masked hypertension or reverse white-coat hypertension (isolated home or 
isolated ambulatory hypertension) is defined as normal OBPM reading (<140/90 
mmHg) but elevated ABPM or HBPM reading (>135/85 mmHg). In other words, 
hypertension is hidden until ABPM or HBPM is performed. Its prevalence is 
about 10% in the general population. It has similar cardiovascular risk as 
sustained hypertension. A study done in France (SHEAF study) found that 9% 
of masked hypertension patients had twice the risk of CVD events as the group 
in whom both office and home BP were controlled (16, 17).   
1.2.1.3 HBPM and its correlation with hypertensive-target organ damage 
HBPM is proven to be useful in predicting the hypertensive-target organ 
damage mainly the CVD events and mortality. A large cohort study in Japan 
showed that HBPM predicted the risk of stroke better than office BP readings. In 
this study, the risk of stroke increased 29% for each 10 mmHg increase in home 
systolic BP readings versus 9% for office readings. Another large cohort study 
found that each 10 mmHg increase above 135/85 mmHg was associated with 
17% increase in risk of cardiovascular disease, even when office blood 
pressure was normal (14). Longitudinal studies found that systolic HBPM was a 
stronger predictor of diabetic nephropathy / end-stage renal disease and death 
(16). 
1.2.2 Effects of HBPM on BP Control: 
In general, office BP reading of <140/90 mmHg is taken as controlled BP. To 
achieve equivalence with clinic-measured BP, home BP readings should be 
adjusted by -5/5mmHg. Thus, a home BP reading of 135/85 mmHg taken at 
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home is equivalent to a reading of 140/90 mmHg in a clinic setting. For home 
BP reading, a mean systolic BP of >135mmHg and/or diastolic BP >85mmHg is 
considered as elevated, whereas systolic BP of <130mmHg and/or diastolic BP 
< 80mmHg respectively, is considered as normal (18).  
BP control among treated hypertensive patients has been reported to vary 
between 5.4% and 58% worldwide (19). In United States, the condition remains 
poor; with approximately only 30% of patients categorized as controlled in spite 
of treatment (20). Similarly in Malaysia, based on National Health and Morbidity 
Survey (NHMS) 2011, only 34.8% of those treated for hypertension achieved 
BP target of control (21). In J-HOME study done in Japan, 42% of the sample 
had their BP controlled by office BP criteria (<140/90 mmHg), and only 34% had 
their home BP control (<135/85 mmHg) (16).  
Home monitoring may improve the BP control by improving the patient’s 
compliance towards treatment (9). HBPM makes patients more aware of their 
BP level, thus may increase their illness perceptions and subsequent health 
behaviours (14, 16, 22).  
In meta-analysis of 18 randomized control trials (RCT), patients using HBPM 
have their BP improved by approximately 2.2 mmHg systolic and 1.9 mmHg 
diastolic BP. Although this reductions are small but it is significant, and it may 
contribute to an overall reduction in hypertensive-related complications (22).  
In another systematic review and meta-analysis of 37 RCT, patients who were 
in home-based BP monitoring group, showed an improvement in both SBP and 
DBP (2.63 mmHg and 1.68 mmHg respectively) as compared to control group 
(23). 
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Cappuccio et al (2004) demonstrated that there was increment in the proportion 
of patients who achieved BP control among those using HBPM rather than 
standard BP monitoring (24). 
Studies done on HBPM intervention alone seems to show a modest effect as 
compared to combined-intervention. Among the important additional co-
interventions include patient education, tele-monitoring / internet communication 
systems, and intensive nurse led follow-up and patient led titration of drugs (14). 
Green BB et al (2008) with three arm intervention study showed  a greater net 
systolic and diastolic BP reduction (-13.2mmHg, -4.6mmHg respectively) and 
improved BP control in HBPM plus secure patient website training plus 
pharmacist care intervention (25). 
McManus (2010) with intervention study of HBPM and self-titration of 
medications combined with tele-monitoring showed that  systolic BP decreased 
by 17.6mmHg in intervention group and 12.2mmHg in control group; with 
difference in between group of 5.4mmHg (14). 
1.2.3 Effects of HBPM on Medication Adherence: 
A potential mechanism towards the achievement of BP control is by improving 
the patient’s medication adherence (16). Medication adherence is “the extent to 
which the medication-taking behaviour of a patient corresponds with agreed 
recommendations from a health care provider” (26). Adherence patients are 
defined as those who accept their physician’s advice to start drug therapy and 
who take their medication at least 80% of the time. Non-adherence means 
constant neglect rather than just temporary forgetfulness or neglect of treatment 
(27).  
8 
 
Multiple factors have been suggested to influence patient adherence to 
prescribed therapies. These include treatment profile (class of drug prescribed, 
number of pills per day, side effects of medication, high number of pills to be 
taken daily), sociodemographic factor (age, gender, low socioeconomic status), 
patients factor (lack of motivation or social support, poor patient’s involvement 
due to lack of knowledge regarding hypertension forgetfulness, absence of 
symptoms, patient’s treatment satisfaction), patients quality of life 
(psychological problems, especially depression) and other health care system 
issues (28) (29) (30).  
Ramli et al found that 56% of the study subjects whom taking anti-
hypertensives, anti-diabetics or anti-asthmatic drugs were non-compliant to their 
medications. Another study which was done at outpatient clinic in Penang 
showed that 51.3% of patients whom being interviewed had poor adherence to 
anti-hypertensives medications (26). 
The evidence to support the effectiveness of HBPM in improving medication 
adherence among hypertensive patients are limited (20). Despite this fact, 
HBPM has been recommended as a good strategy to improve patient’s 
adherence to antihypertensive medications (20).   
Review of 11 RCTs by Ogedegbe and Schoenthaler reported that 54% of the 
trial has significant improvement in medication adherence attributed to the 
intervention. Five out of six studies were complex interventions and the 
intervention effects more seen in the trials that tested HBPM together with other 
adherence-enhancing strategies (16). 
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McKenney et al found that the mean compliance for the intervention group was 
significantly higher than that of the control group (95.1% vs 76.8%; p=0.0002) 
and this difference was greater as the number of compliance techniques 
increased (20). 
Shulman reported that patient’s compliance is better among those who feel that 
they are actively involved in their care. Similarly, Nessman et al showed that 
patients who monitor their BP at home and choose their own medication in a 
group sessions (according to a standard step-wise regime), has a better BP 
control and higher compliance toward treatment (31).  
Therefore, HBPM is recommended for the evaluation of the treatment response 
and it may also improve the medication adherence. In addition, it also has the 
potential to improve the quality of care, thus reducing the number of clinic visits 
and resulting in the reduction of overall healthcare cost (16).  
1.3 JUSTIFICATION AND RATIONALE 
With all the evidence summarized above, HBPM is proven to be a useful 
strategy to improve the care of hypertensive patients. It is the time for our 
patients to practice HBPM as part of their self-care in the same way that home 
blood glucose monitoring is performed by the diabetic patient. 
Majority of studies that examined the effects of HBPM were conducted in the 
western countries. Many of these studies have shown promising results towards 
the improvement of BP control and medication adherence. 
Up to our knowledge; there is not much intervention study on HBPM done in 
Malaysia, in particular study on its effect towards BP control and medication 
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adherence. Therefore, we are interested in looking into our own local data. 
Findings from this study can be a platform for future research on HBPM in 
Malaysia and we are hoping that we can come out with a proper HBPM module 
in order to educate our patients on self BP monitoring.  
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CHAPTER 2: OBJECTIVES AND HYPOTHESIS 
2.1 OBJECTIVES 
2.1.1 GENERAL OBJECTIVE: 
To evaluate the effect of home blood pressure monitoring (HBPM) on office BP 
and medication adherence among hypertensive patients attending Primary Care 
Clinic in University Hospital 
2.1.2 SPECIFIC OBJECTIVES: 
 To assess the effect of HBPM on office BP: 
i. To determine changes of mean SBP (of office BP reading) within HBPM 
and control group from baseline to 2 months period 
ii. To determine changes of mean DBP (of office BP reading) within HBPM 
and control group from baseline to 2 months period 
iii. To compare changes of mean SBP (of office BP reading) between 
HBPM and control group at 2 months period 
iv. To compare changes of mean DBP (of office BP reading) between 
HBPM and control group at 2 months period 
To assess the effect of HBPM on medication adherence: 
v. To determine changes of mean medication adherence score (MAS) 
within HBPM and control group from baseline to 2 months period 
vi. To compare changes of mean medication adherence score (MAS) 
between HBPM and control group at 2 months period 
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2.2 HYPOTHESIS 
2.2.1 Null hypothesis:  
i. There are no significant differences  in mean SBP (of office BP reading) 
within HBPM and control group from baseline to 2 months period 
ii. There are no significant differences  in mean DBP (of office BP reading) 
within HBPM and control group from baseline to 2 months period 
iii. There are no significant differences in changes of mean SBP (of office 
BP reading) between HBPM and control group at 2 months period 
iv. There are no significant differences in changes of mean DBP (of office 
BP reading) between HBPM and control group at 2 months period 
v. There are no significant differences in mean medication adherence score 
(MAS) within HBPM and control group from baseline to 2 months period 
vi. There are no significant differences in changes of mean medication 
adherence score (MAS) between HBPM and control group at 2 months 
period  
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CHAPTER 3: METHODOLOGY 
3.1 STUDY DESIGN 
Randomized, non-blinded (open-labeled) two-arm parallel controlled trial 
3.2 STUDY DURATION 
23rd December 2014 until 17th March 2015 
3.3 OPERATIONAL AREA 
Primary care clinic in university hospital 
3.4 REFERENCE POPULATION 
All hypertensive patients in primary care clinic in university hospital  
3.5 SOURCE POPULATION 
All hypertensive patients who attended primary care clinic in university hospital   
3.6 SAMPLING FRAME 
All hypertensive patients who attended primary care clinic in university hospital 
from 23rd December 2014 to 17th March 2015 who fulfilled the inclusion and 
exclusion criteria. The criteria applied for both intervention and control group. 
Inclusion Criteria: 
i. Aged 18 years and above 
ii. Stage I and stage II essential hypertension 
iii. On antihypertensive medications 
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Exclusion Criteria: 
i. Secondary hypertension 
ii. Resistant hypertension 
iii. Unstable cerebrovascular/cardiovascular disease 
iv. Chronic kidney disease stage IV and V or end-stage renal disease  
v. Pregnancy 
vi. Previous usage of home blood pressure monitoring (HBPM) (prior to 
participating in this study) 
3.7 SAMPLE SIZE CALCULATION 
The sample size calculations were done for objectives of the study and the 
biggest sample size was chosen (as shown in table 1). Sample size calculations 
were done using Power and Sample Size Calculation Software for comparing 
two means.  
For objective 1, sample size calculation was to determine changes of mean 
SBP (of office BP reading) within HBPM and control group from baseline to 2 
months period.  
Based on study by Mὰrquez et al (2004), the standard deviation of mean SBP 
(post-intervention) was 11.2mmHg. The other parameters were as follows: 
α  = Level of significance : 0.05 
Power (1-β) = 0.8 
σ              = Standard deviation for SBP (post-intervention) was 11.2mmHg  
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δ  = Expected detectable difference in the mean SBP between  
HBPM group and control group was10.0mmHg 
m                  = (ratio between HBPM group & control group): 1 
After considering 20% of non-response rate, the calculated sample size was 25 
subjects per group. Therefore the total sample size required for objective 1 was 
50 subjects. 
Table 1: Sample size calculation for objectives of the study 
Parameter 
to 
compare 
Standard 
deviation 
(σ) 
Detectable 
difference 
(δ) 
Ratio Sample 
size 
+ 20% drop-
out 
SBP 11.2 10 1 21 25 per 
group 
DBP 7.6 5 1 37 44 per 
group 
MAS 18.1 12 1 37 44 per 
group 
 
The biggest sample size was from the calculation of mean DBP and mean 
Medication Adherence Score (MAS). Therefore the total sample size required 
for this study was 88 subjects (44 patients per group). 
3.8 RESEARCH TOOLS 
3.8.1 Respondent Pro Forma Sheet: 
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This Respondent Pro Forma Sheet consisted of four sections which include 
information regarding socio-demographic data; patient’s medical profile; 
anthropometric measurements and office BP reading and New Medication 
Adherence Scale questionnaire. The patient was interviewed and the 
researcher filled-in the required information. The following data were obtained 
during the interview session: 
a) Socio-demographic data including age, gender, race, marital status, 
background educational level, occupation and smoking status  
b) Patient’s medical profile (obtained from patient’s medical record ) 
including duration of hypertension, number of anti-hypertensive taken, 
comorbid of diabetes mellitus and dyslipidemia  
c) Anthropometric measurements including measurement of height and 
weight (to obtain the Body Mass Index), waist circumference; and office 
BP reading were documented. All the measurements were taken using 
the standard protocol. 
d) New Medication Adherence Scale questionnaire consisting of seven 
questions.   
3.8.2 Tools for anthropometric measurement 
i. Weight and height measurement: 
A standardized secca scale was used to measure the patient’s weight in 
kg and height in cm.  
Patients were asked to empty their pockets and to stand on bare feet 
before the measurements were taken. Body mass index (BMI) was 
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calculated from the measurement of weight and height by using the 
formula: BMI = Weight (kg) / Height2 (m) 2  
ii. Waist Circumference: 
A soft tape was used to measure the patient’s waist circumference in cm. 
The patients were asked to stand with their feet 25 to 30cm apart with 
weight evenly distributed. The arms hang on each side of the body at an 
angle of 300. The measurement was taken at the end of a normal 
expiration, at mid-distance circumferentially between the lowest rib 
margins and top of iliac crest. The measurement was made twice, taking 
the average as the final reading. 
3.8.3 Tools for BP measurement 
i. Office BP measurement:  
Automatic BP monitor Omron model HEM-7203 was used to measure 
the office BP.  
The machine was properly validated, maintained and regularly 
recalibrated according to the manufacturers’ instruction by maintenance 
technician. An appropriate BP arm-cuff with correct size was used during 
the measurement.  
For the measurement, the patients were asked to be seated in a correct 
technique (seated on a chair with legs uncrossed, with his/her back 
supported and arm outstretched on the table). They were asked to be 
rested, not talking and relaxed for at least 5 minutes prior to the BP 
measurement. The BP machine was placed at the heart level during the 
measurement. Two BP recordings were obtained from the right arm of 
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the patients at 5 minutes interval. The mean of this two office BP reading 
was taken at baseline and at 2 months of intervention.  
ii. Home BP monitoring: 
Automatic BP monitor Omron model HEM-7120 was used for 
measurement of home BP. 
For this purpose, the patients were provided with a new set of Omron 
HEM-7120 and a BP diary. Each set of Omron HEM-7120 consisted of a 
main unit, arm cuff, instruction manual and 4 “AA” batteries.  
Omron HEM-7120 used an IntelliSense Technology in which it applied 
the right amount of pressure for fast, accurate and more comfortable 
measurements. It used oscillometric method for the measurement and 
able to measure the pressure range from 0 to 299mmHg and pulse of 40 
to 180 beats per minute. This model was listed under Malaysian Ministry 
of Health and approved by British Hypertension Society (www.bhsoc.org) 
for usage at home and may also be used in the clinic setting (refer 
Appendix 4 for HBPM diary). 
3.8.4 New Medication Adherence Scale Questionnaire 
This questionnaire consented for use in this study by Ramli et al, who done a 
study on ‘Medication adherence among hypertensive patients of primary health 
clinics in Malaysia’ in 2012. The questions in the Medication Adherence Scale 
used in the study were developed using two different adherence questionnaires, 
which were the Hill-Bone Adherence to Blood Pressure Therapy Scale and the 
8-item Morisky Medication Adherence Scale MMAS.  
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The 8-item Morisky Medication Adherence Scale MMAS was one of the most 
frequently used self-reporting tools to measure patients’ adherence to the 
prescribed medicine and it contained eight questions to assess the patients’ 
adherence towards the behavior of medication-taken in an outpatient setting. 
The Hill-Bone Compliance to Blood Pressure Therapy Scale was another self-
reporting tool and it contained 14 questions including eight questions that 
assessed medication-taking behaviors in hypertensive patients. High reliability 
and validity had been reported for these two tools of adherence measurement. 
The Hill-Bone scale had been shown to have good internal consistency and 
reliability with a Cronbach’s α of 0.68. 
This New Medication Adherence Scale Questionnaire had seven questions in 
total in which they were selected from the above two questionnaires and 
condensed to form the modified Medication Adherence Scale, relevant to the 
local setting. Prior to its use in the study, it was subjected to evaluation and 
validation. Cronbach‘s α was calculated to be 0.782, reflecting a good internal 
consistency and reliability. Interrater agreements (between the two interviewers) 
indicated good consistency with the Kappa value of 0.796. There were two 
version of this questionnaire: New Medication Adherence Scale Questionnaire 
(English version) and ‘Borang Penilaian Komplian Ubat-Ubatan’ (Malay 
version).   
In this New Medication Adherence Scale Questionnaire, the patients were 
required to choose their responses from a set of possible answers. Each 
question in this questionnaire had a four-point Likert-type response format. 
Each response carried a score: 1= selalu (all of the time), 2= kerap kali (most of 
the time), 3= kadang-kadang (some of the time), 4= tidak pernah (none of the 
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time). The total scores were added for each patient and it could range from 7 
(minimum) to 28 (maximum). Lower scores reflected poorer adherence to 
medication therapy. A full score of 28 or a score of 27 (due to 1 point deducted 
from any one of the “unintentional adherence” questions, which were question 1 
or question 6), were defined as adherers. A score of 27 (due to 1 point 
deducted from other questions) or a score of 26 and below were categorized as 
non-adherers (refer Appendix 3 Section D for New Medication Adherence Scale 
Questionnaire). 
3.9 SAMPLING METHOD 
All hypertensive patients who came to the primary care clinic in university 
hospital during one month period of data collection (from 23rd December 2014 
till 20th January 2015) were targeted for recruitment into the study. A total 
number of 420 patients with hypertension were screened for fulfillment of 
inclusion and exclusion criteria inside the consultation room. Prior to that, each 
of the doctors in every consultation room was briefed on the patients’ selection 
criteria and flow of the eligible patient. Those who fulfilled the above criteria 
were subsequently referred to the researcher for further explanation regarding 
the study. From total of 420 patients, 140 patients fulfilled the criteria and 52 of 
them not consented / refused to join the study. Therefore, 88 patients who gave 
their consent were enrolled into the study.  
From the consultation room, the patients were taken to another room, which 
was more quiet and comfortable. Inside the room, the researcher gave related 
information and comprehensive explanation regarding the study to each of the 
eligible patients. A standardize information were given to each of them. They 
21 
 
were given ample of time to consider their decision whether to involve or not in 
the study. For those who were interested in participating in the study, a written 
informed consent was obtained from them. 
Subsequently, the decision to recruit the patients into either HBPM group or 
control group was based on the randomization table (elaborated in the 
randomization method section 3.10). The patients were only identified based on 
their entry number and were allocated into the specific group as they were 
recruited. There were total of 88 eligible subjects with 44 subjects in each 
group. 
3.10 RANDOMIZATION METHOD 
The total numbers of eligible subjects were randomized either into the home BP 
monitoring (HBPM) group or control group based on randomization table that 
had been prepared earlier. This randomization table which used the 
randomization blocks of four was produced by computer-generated 
randomization method (refer Appendix 5 for Randomization Table). 
3.11 DATA COLLECTION PROCEDURE 
Generally, there were two visits throughout this study period for both groups 
(baseline and at two months after the intervention). However; for HBPM group, 
they had an interim follow-up at one month from the baseline date through a 
phone call. At baseline, the patients from both groups were interviewed by the 
researcher. The Respondent Pro forma Sheet was then filled-up and the patient 
needed to answer the New Medication Adherence Score, assisted by the 
researcher. The patients’ medical records were reviewed at the same time and 
their related medical profiles were noted. The clinical measurements of patient’s 
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height, weight, and waist circumference; and office BP were taken according to 
the standard protocol. All the above baseline data were recorded in the case 
report form. In addition to the above measures, both groups were given a brief 
counselling regarding the lifestyle modification including advice on physical 
activities or exercise and low-salt diet consumption in relation to the 
management of hypertension. For both groups, their anti-hypertensive 
medications dosages were maintained (no increments of dosages or additional 
of anti-hypertensive medications throughout the study period).        
For the control group, the baseline session took about 20 minutes to be 
completed. Generally, the control group followed the usual care in the clinic 
provided by their healthcare provider. They were given an appointment date to 
be seen again in two months’ time for the second visit of the study.  
For HBPM group, the baseline session took about 30 minutes to be completed. 
They were given explanation regarding the home BP monitoring protocol as 
outlined in this study. They were introduced to the device; the automatic BP 
monitor Omron model HEM-7120, and they were shown on how to operate the 
machine. The appropriate BP arm-cuff size was given to each of them. The 
patients and their caretaker were explained on proper technique of performing 
home BP measurement.  
The similar principle of office BP measurement was applied for home BP 
measurement. In addition, the patients were instructed to take home BP reading 
of ideally seven days in a week. The measurements were done at about the 
same time in two occasions per day, once in the morning and once in the 
evening. The morning reading was taken before the drug intake (from 6am to 12 
23 
 
noon), whereas the evening reading was taken before the meal intake (from 
6pm to 12 midnight).  
For each occasion, the patients need to perform two BP measurements taken at 
1 to 2 minutes apart. After each measurement, the results need to be 
immediately recorded in a home BP diary given to them (Appendix 4). They 
were asked to perform this HBPM throughout the study period within two 
months duration. The patients in HBPM group were also given an appointment 
date in two months’ time for the second visit of the study in which during that 
time they need to return back the BP machine and their home BP diary.   
For HBPM group, there was an interim follow-up through a phone call at one 
month from baseline. The patients were asked regarding the progress of the 
home BP monitoring, any concerns or problems related to the HBPM. The 
patients were reminded to continue their home BP monitoring as instructed until 
the completion of the study. 
Both groups were seen again at two months from the baseline visit for the post-
intervention data collection. During this second visit, two readings of office BP 
were measured and all the participants were required to answer again the New 
Medication Adherence Scale Questionnaire. For HBPM group, their home BP 
diaries were reviewed. All the post-intervention data were recorded in the case 
report form. The study ended at this point. Figure 1 showed the flow chart of the 
study.    
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Figure 1: Flow Chart of the Study 
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